Telek Béla, Rejto László, Batár Péter, Reményi Gyula, Szász Róbert, Kiss Attila, Udvardy Miklós
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Általános Orvostudományi Kar II., Belgyógyászati Klinika, Hematológiai Tanszék Debrecen Pf. 20 4012.
Orv Hetil. 2011 Jun 12;152(24):958-63. doi: 10.1556/OH.2011.29135.
Understanding the pathogenesis and refine the treatment of chronic lymphocytic leukemia have been tremendously improved in the past decade. Treatment outcome and estimated prognosis have become more accurate due to the advanced molecular biological techniques and the classical prognostic markers. Incorporation of fludarabine and rituximab into the standard protocols fundamentally improved treatment outcome in chronic lymphocytic leukemia. Chemoimmunotherapy has improved not only the remission rates but had a significant impact on overall survival, as well. Eliminating residual leukemia and achieving complete hematological remissions at such high rates establish potential background for cure. Still, a great deal of dispute has been emerged regarding everyday clinical practice. Authors present their institutional experiences and review the literature.
在过去十年中，对慢性淋巴细胞白血病发病机制的理解以及治疗方法的完善有了极大的进步。由于先进的分子生物学技术和经典的预后标志物，治疗结果和预估预后变得更加准确。将氟达拉滨和利妥昔单抗纳入标准方案从根本上改善了慢性淋巴细胞白血病的治疗结果。化学免疫疗法不仅提高了缓解率，也对总生存期产生了重大影响。以如此高的比率消除残留白血病并实现完全血液学缓解为治愈奠定了潜在基础。然而，在日常临床实践中仍存在大量争议。作者介绍了他们机构的经验并对文献进行了综述。
